These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34798979)

  • 21. Surveillance for familial pancreatic cancer.
    de Vos tot Nederveen Cappel WH; Lagendijk MA; Lamers CB; Morreau H; Vasen HF
    Scand J Gastroenterol Suppl; 2003; (239):94-9. PubMed ID: 14743890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
    Krepline AN; Geurts JL; Akinola I; Christians KK; Clarke CN; George B; Ritch PS; Khan AH; Hall WA; Erickson BA; Griffin MO; Evans DB; Tsai S
    HPB (Oxford); 2020 Dec; 22(12):1745-1752. PubMed ID: 32354656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    Matsubayashi H; Takaori K; Morizane C; Kiyozumi Y
    Gut Liver; 2019 Sep; 13(5):498-505. PubMed ID: 30917631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.
    Goehringer C; Sutter C; Kloor M; Gebert J; Slater EP; Keller M; Treiber I; Ganschow P; Kadmon M; Moog U
    Fam Cancer; 2017 Apr; 16(2):303-309. PubMed ID: 27838800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
    Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial pancreatic cancer: from genes to improved patient care.
    Hruban RH; Klein AP; Eshleman JR; Axilbund JE; Goggins M
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):81-8. PubMed ID: 19072437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial pancreatic cancer.
    Klein AP; Hruban RH; Brune KA; Petersen GM; Goggins M
    Cancer J; 2001; 7(4):266-73. PubMed ID: 11561603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic predisposition to pancreatic cancer.
    Ghiorzo P
    World J Gastroenterol; 2014 Aug; 20(31):10778-89. PubMed ID: 25152581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.
    Stoffel EM; McKernin SE; Brand R; Canto M; Goggins M; Moravek C; Nagarajan A; Petersen GM; Simeone DM; Yurgelun M; Khorana AA
    J Clin Oncol; 2019 Jan; 37(2):153-164. PubMed ID: 30457921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
    Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
    J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Familial pancreatic cancer].
    Zalatnai A
    Magy Onkol; 2006; 50(2):163-8. PubMed ID: 16888680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
    Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
    J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
    Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
    J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status.
    Antwi SO; Fagan SE; Chaffee KG; Bamlet WR; Hu C; Polley EC; Hart SN; Shimelis H; Lilyquist J; Gnanaolivu RD; McWilliams RR; Oberg AL; Couch FJ; Petersen GM
    J Natl Cancer Inst; 2019 Mar; 111(3):264-271. PubMed ID: 29982661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.